KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Payables (2016 - 2025)

Neogenomics (NEO) has disclosed Payables for 16 consecutive years, with $23.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Payables fell 89.62% year-over-year to $23.1 million, compared with a TTM value of $23.1 million through Dec 2025, down 89.62%, and an annual FY2025 reading of $23.1 million, down 89.62% over the prior year.
  • Payables was $23.1 million for Q4 2025 at Neogenomics, up from $22.6 million in the prior quarter.
  • Across five years, Payables topped out at $222.4 million in Q4 2024 and bottomed at $13.7 million in Q3 2022.
  • Average Payables over 5 years is $60.2 million, with a median of $21.6 million recorded in 2022.
  • The sharpest move saw Payables soared 1189.84% in 2024, then tumbled 89.62% in 2025.
  • Year by year, Payables stood at $17.9 million in 2021, then grew by 14.45% to $20.5 million in 2022, then dropped by 0.86% to $20.3 million in 2023, then soared by 993.66% to $222.4 million in 2024, then crashed by 89.62% to $23.1 million in 2025.
  • Business Quant data shows Payables for NEO at $23.1 million in Q4 2025, $22.6 million in Q3 2025, and $27.5 million in Q2 2025.